Agios Pharmaceuticals
AGIO
196 hedge funds and large institutions have $2.66B invested in Agios Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 79 increasing their positions, 55 reducing their positions, and 40 closing their positions.
147% more call options, than puts
Call options by funds: $42.5M | Put options by funds: $17.2M
44% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 55
3.81% more ownership
Funds ownership: 95.99% → 99.8% (+3.8%)
6% less funds holding
Funds holding: 208 → 196 (-12)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
30% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 40
38% less capital invested
Capital invested by funds: $4.29B → $2.66B (-$1.63B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$55.2M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$42M |
| 3 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$40.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22.9M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$35.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$29.5M |
| 3 |
DM
Deerfield Management
New York
|
-$26.9M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$19.4M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$18.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIL
226
AGF Investments LLC
Toronto,
Ontario, Canada
| – | -$8K | -104 | Closed |
|
227
Fifth Third Bancorp
Cincinnati,
Ohio
| – | -$6K | -83 | Closed |
|
|
SPIA
228
Steward Partners Investment Advisory
New York
| – | -$1K | -9 | Closed |
|
229
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$1K | -8 | Closed |
|
|
AIA
230
Alera Investment Advisors
Deerfield,
Illinois
| – | +$309 | +5 | New |
|
|
IFAM
231
Institutional & Family Asset Management
Fort Collins,
Colorado
| – | +$617 | +10 | New |
|
AGIO Hedge Fund Activity: Q4 2018 in Review
196 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q4 2018, worth a combined $2.66B — down 38% from $4.29B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of AGIO and 28 opened new positions — a net loss of 12 holders — while 55 trimmed existing stakes and 79 added.
The largest buyer was JP Morgan Chase, adding an estimated $55.2M. The largest seller was Wells Fargo, cutting an estimated $35.1M.
- 196 institutional investors held Agios Pharmaceuticals (AGIO) as of Q4 2018, down from 208 in Q3 2018.
- Funds reported $2.66B of Agios Pharmaceuticals stock for Q4 2018, down 38% quarter-over-quarter.
- 28 funds opened new Agios Pharmaceuticals positions in Q4 2018 and 40 closed out, a net change of -12 holders.
- The largest Agios Pharmaceuticals buyer in Q4 2018 was JP Morgan Chase, an estimated $55.2M added.
- The largest Agios Pharmaceuticals seller in Q4 2018 was Wells Fargo, an estimated $35.1M sold.
Based on aggregated 13F filings for Q4 2018.